Polycomb Repressive Complex 2 in Oncology

Overview

Journal Cancer Treat Res

Publisher Springer

Specialties Oncology
Pharmacology

Date 2023 Dec 19

PMID 38113005

Authors

Yiran Guo

Yao Yu

Gang Greg Wang

Affiliations

Soon will be listed here.

Abstract

Dynamic regulation of the chromatin state by Polycomb Repressive Complex 2 (PRC2) provides an important mean for epigenetic gene control that can profoundly influence normal development and cell lineage specification. PRC2 and PRC2-induced methylation of histone H3 lysine 27 (H3K27) are critically involved in a wide range of DNA-templated processes, which at least include transcriptional repression and gene imprinting, organization of three-dimensional chromatin structure, DNA replication and DNA damage response and repair. PRC2-based genome regulation often goes wrong in diseases, notably cancer. This chapter discusses about different modes-of-action through which PRC2 and EZH2, a catalytic subunit of PRC2, mediate (epi)genomic and transcriptomic regulation. We will also discuss about how alteration or mutation of the PRC2 core or axillary component promotes oncogenesis, how post-translational modification regulates functionality of EZH2 and PRC2, and how PRC2 and other epigenetic pathways crosstalk. Lastly, we will briefly touch on advances in targeting EZH2 and PRC2 dependence as cancer therapeutics.

Citing Articles

EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.

Corbin J, Yu X, Jin J, Cai L, Wang G Oncogene. 2024; 43(36):2722-2736.

PMID: 39112519 DOI: 10.1038/s41388-024-03119-9.

Implications in Cancer of Nuclear Micro RNAs, Long Non-Coding RNAs, and Circular RNAs Bound by PRC2 and FUS.

Swaminathan G, Rogel-Ayala D, Armich A, Barreto G Cancers (Basel). 2024; 16(5).

PMID: 38473229 PMC: 10930775. DOI: 10.3390/cancers16050868.

References

Blackledge N, Klose R . The molecular principles of gene regulation by Polycomb repressive complexes. Nat Rev Mol Cell Biol. 2021; 22(12):815-833. PMC: 7612013. DOI: 10.1038/s41580-021-00398-y. View

Chi P, Allis C, Wang G . Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10(7):457-69. PMC: 3262678. DOI: 10.1038/nrc2876. View

Margueron R, Reinberg D . The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469(7330):343-9. PMC: 3760771. DOI: 10.1038/nature09784. View

Parreno V, Martinez A, Cavalli G . Mechanisms of Polycomb group protein function in cancer. Cell Res. 2022; 32(3):231-253. PMC: 8888700. DOI: 10.1038/s41422-021-00606-6. View

Pasini D, Di Croce L . Emerging roles for Polycomb proteins in cancer. Curr Opin Genet Dev. 2016; 36:50-8. DOI: 10.1016/j.gde.2016.03.013. View

Piunti A, Shilatifard A . The roles of Polycomb repressive complexes in mammalian development and cancer. Nat Rev Mol Cell Biol. 2021; 22(5):326-345. DOI: 10.1038/s41580-021-00341-1. View

Schuettengruber B, Bourbon H, Di Croce L, Cavalli G . Genome Regulation by Polycomb and Trithorax: 70 Years and Counting. Cell. 2017; 171(1):34-57. DOI: 10.1016/j.cell.2017.08.002. View

Vizan P, Beringer M, Ballare C, Di Croce L . Role of PRC2-associated factors in stem cells and disease. FEBS J. 2014; 282(9):1723-35. DOI: 10.1111/febs.13083. View

Wang G, Allis C, Chi P . Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med. 2007; 13(9):363-72. DOI: 10.1016/j.molmed.2007.07.003. View

10.

Wang G, Allis C, Chi P . Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. Trends Mol Med. 2007; 13(9):373-80. PMC: 4337864. DOI: 10.1016/j.molmed.2007.07.004. View

11.

Zhao S, Allis C, Wang G . The language of chromatin modification in human cancers. Nat Rev Cancer. 2021; 21(7):413-430. PMC: 10507815. DOI: 10.1038/s41568-021-00357-x. View

12.

Cao R, Zhang Y . SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell. 2004; 15(1):57-67. DOI: 10.1016/j.molcel.2004.06.020. View

13.

Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D . Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002; 16(22):2893-905. PMC: 187479. DOI: 10.1101/gad.1035902. View

14.

Yu J, Lee C, Oksuz O, Stafford J, Reinberg D . PRC2 is high maintenance. Genes Dev. 2019; 33(15-16):903-935. PMC: 6672058. DOI: 10.1101/gad.325050.119. View

15.

Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones R . Role of histone H2A ubiquitination in Polycomb silencing. Nature. 2004; 431(7010):873-8. DOI: 10.1038/nature02985. View

16.

Baile F, Gomez-Zambrano A, Calonje M . Roles of Polycomb complexes in regulating gene expression and chromatin structure in plants. Plant Commun. 2022; 3(1):100267. PMC: 8760139. DOI: 10.1016/j.xplc.2021.100267. View

17.

Chen Z, Zhang Y . Maternal H3K27me3-dependent autosomal and X chromosome imprinting. Nat Rev Genet. 2020; 21(9):555-571. PMC: 7717073. DOI: 10.1038/s41576-020-0245-9. View

18.

Guo Y, Zhao S, Wang G . Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction. Trends Genet. 2021; 37(6):547-565. PMC: 8119337. DOI: 10.1016/j.tig.2020.12.006. View

19.

Inoue A, Jiang L, Lu F, Suzuki T, Zhang Y . Maternal H3K27me3 controls DNA methylation-independent imprinting. Nature. 2017; 547(7664):419-424. PMC: 9674007. DOI: 10.1038/nature23262. View

20.

Almeida M, Bowness J, Brockdorff N . The many faces of Polycomb regulation by RNA. Curr Opin Genet Dev. 2020; 61:53-61. PMC: 7653676. DOI: 10.1016/j.gde.2020.02.023. View